Shanghai Kanda Biotechnology Co., Ltd.
4 clinical trials · Sponsor
◉ Watch Shanghai Kanda Biotechnology Co., Ltd.
| Record | Firm | Date |
|---|---|---|
| KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors (NCT05906524) | Shanghai Kanda Biotechnology Co., Ltd. | 2024-04-15 |
| A Study of KD6005 in Healthy Participants and Participants With Rheumatoid Arthritis (RA) (NCT06213259) | Shanghai Kanda Biotechnology Co., Ltd. | 2024-01-06 |
| KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma (NCT05723432) | Shanghai Kanda Biotechnology Co., Ltd. | 2023-03-22 |
| Clinical Study of KD6001 in Advanced Solid Tumours (NCT05230290) | Shanghai Kanda Biotechnology Co., Ltd. | 2020-09-10 |
Track Shanghai Kanda Biotechnology Co., Ltd. automatically
Every clearance here is in the API, with alerts when new ones post.